论文部分内容阅读
目的探讨SIL-2R在癫痫患者血清中含量及临床意义。方法用ELISA检测了158例癫痫患者血清SIL-2R含量。结果癫痫患者血清SIL-2R含量明显高于对照组（P＜0.05），癫痫患者男女之间血清SIL-2R含量无差异（P＞0.05）;癫痫大发作型、精神运动型、婴儿痉挛症和癫痫持续状态SIL-2R均高于对照组（P＜0.05或P＜0.01），其他类型与对照组无差异（P＞0.05）;原发性癫痫和未服AEDs患者血清SIL-2R含量高于对照组（P＜0.01），继发性癫痫与对照组无差异（P＞0.05）;经抗癫痫药物治疗控制发作癫痫患者血清SIL-2R含量减低，与对照组无差异（P＞0.05）。结论血清SIL-2R可能成为探测癫痫发病机制的一个新课题和作为痫性变化监测的一个新指标。
Objective To investigate the content and clinical significance of SIL-2R in sera of patients with epilepsy. Methods The levels of serum SIL-2R in 158 epileptic patients were detected by ELISA. Results Serum levels of SIL-2R in epilepsy patients were significantly higher than those in control group (P <0.05). There was no significant difference in serum SIL-2R between men and women in epilepsy patients (P> 0.05). The incidence of seizures, psychomotor, infantile spasms and The levels of SIL-2R in status epilepticus were significantly higher than those in control group (P <0.05 or P <0.01), while those in other groups were no significant difference (P> 0.05). The levels of serum SIL-2R in patients with primary epilepsy and without AEDs were higher than those in control group The levels of serum SIL-2R in patients with epilepsy were lower than those in control group (P <0.01). There was no significant difference between the control group and the control group (P> 0.05). Conclusion Serum SIL-2R may be a new topic for detecting the pathogenesis of epilepsy and as a new indicator of epileptiform changes.